HilleVax Inc (NASDAQ: HLVX)’s stock price has increased by 6.04 compared to its previous closing price of 14.07. However, the company has seen a 2.90% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-05 that BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Is It Worth Investing in HilleVax Inc (NASDAQ: HLVX) Right Now?
The stock has a 36-month beta value of 0.71. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HLVX is 7.81M, and at present, short sellers hold a 5.74% of that float. On April 12, 2024, the average trading volume of HLVX was 128.55K shares.
HLVX’s Market Performance
The stock of HilleVax Inc (HLVX) has seen a 2.90% increase in the past week, with a -17.34% drop in the past month, and a -1.26% fall in the past quarter. The volatility ratio for the week is 5.39%, and the volatility levels for the past 30 days are at 6.05% for HLVX. The simple moving average for the past 20 days is -6.76% for HLVX’s stock, with a 2.85% simple moving average for the past 200 days.
Analysts’ Opinion of HLVX
Many brokerage firms have already submitted their reports for HLVX stocks, with H.C. Wainwright repeating the rating for HLVX by listing it as a “Buy.” The predicted price for HLVX in the upcoming period, according to H.C. Wainwright is $28 based on the research report published on December 13, 2023 of the previous year 2023.
HLVX Trading at -7.70% from the 50-Day Moving Average
After a stumble in the market that brought HLVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.21% of loss for the given period.
Volatility was left at 6.05%, however, over the last 30 days, the volatility rate increased by 5.39%, as shares sank -17.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.44% upper at present.
During the last 5 trading sessions, HLVX rose by +2.90%, which changed the moving average for the period of 200-days by -10.50% in comparison to the 20-day moving average, which settled at $15.85. In addition, HilleVax Inc saw -7.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HLVX starting from Kohli Aditya, who sale 6,000 shares at the price of $14.44 back on Apr 05 ’24. After this action, Kohli Aditya now owns 789,776 shares of HilleVax Inc, valued at $86,640 using the latest closing price.
Frazier Life Sciences X, L.P., the 10% Owner of HilleVax Inc, purchase 8,850 shares at $14.50 during a trade that took place back on Apr 04 ’24, which means that Frazier Life Sciences X, L.P. is holding 8,544,187 shares at $128,325 based on the most recent closing price.
Stock Fundamentals for HLVX
The total capital return value is set at -0.42. Equity return is now at value -46.39, with -37.35 for asset returns.
Based on HilleVax Inc (HLVX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.06. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -139.19.
Currently, EBITDA for the company is -131.19 million with net debt to EBITDA at 1.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.62.
Conclusion
To sum up, HilleVax Inc (HLVX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
